Tenax Therapeutics (TENX) and Its Competitors Head-To-Head Analysis

Tenax Therapeutics (NASDAQ: TENX) is one of 32 publicly-traded companies in the “Commercial physical research” industry, but how does it contrast to its rivals? We will compare Tenax Therapeutics to related businesses based on the strength of its dividends, analyst recommendations, institutional ownership, earnings, profitability, valuation and risk.


This table compares Tenax Therapeutics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Tenax Therapeutics N/A -175.30% -156.52%
Tenax Therapeutics Competitors -264.40% -15.96% -9.71%

Risk and Volatility

Tenax Therapeutics has a beta of 1.41, suggesting that its share price is 41% more volatile than the S&P 500. Comparatively, Tenax Therapeutics’ rivals have a beta of 3.58, suggesting that their average share price is 258% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings for Tenax Therapeutics and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tenax Therapeutics 0 0 0 0 N/A
Tenax Therapeutics Competitors 172 718 1527 70 2.60

As a group, “Commercial physical research” companies have a potential upside of 8.93%. Given Tenax Therapeutics’ rivals higher probable upside, analysts clearly believe Tenax Therapeutics has less favorable growth aspects than its rivals.

Earnings and Valuation

This table compares Tenax Therapeutics and its rivals gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Tenax Therapeutics N/A -$6.81 million -0.16
Tenax Therapeutics Competitors $1.22 billion $42.30 million 17.18

Tenax Therapeutics’ rivals have higher revenue and earnings than Tenax Therapeutics. Tenax Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Institutional and Insider Ownership

16.3% of Tenax Therapeutics shares are held by institutional investors. Comparatively, 45.6% of shares of all “Commercial physical research” companies are held by institutional investors. 10.4% of Tenax Therapeutics shares are held by company insiders. Comparatively, 15.9% of shares of all “Commercial physical research” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.


Tenax Therapeutics rivals beat Tenax Therapeutics on 9 of the 10 factors compared.

About Tenax Therapeutics

Tenax Therapeutics, Inc., a specialty pharmaceutical company, focused on the identification, development, and commercialization of a portfolio of products for the critical care market in the United States and Canada. It focuses on the development and commercialization of pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion/5ml vial for use in the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.

Receive News & Ratings for Tenax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenax Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.